Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
puribaptide
- Development stage
- Phase 1
- Lead developer
- Shaanxi Maike Aote Technology
- Modality
- Peptides
- Administration
- Intravenous
01
Overview
Puribaptide is a synthetic cyclic peptide and a platelet glycoprotein IIb/IIIa (GP IIb/IIIa) receptor antagonist. Developed by Shaanxi Maike Aote Technology Co., Ltd., it is intended for the treatment of acute coronary syndrome (ACS) and for patients undergoing percutaneous coronary intervention (PCI). The drug works by binding to the GP IIb/IIIa receptor on the surface of platelets, which prevents the binding of fibrinogen and other adhesive ligands, thereby inhibiting platelet aggregation and thrombus formation. Puribaptide is administered via intravenous injection and has been evaluated in Phase 1 clinical trials to assess its safety, pharmacokinetics, and pharmacodynamic effects on platelet function and coagulation.
- Other names
- 普瑞巴肽
02
Targets
GPIIb/IIIa (Integrin alpha-IIb/beta-3)
Beyond the preview
Go deeper on puribaptide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on puribaptide.